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Short title:   
Diagnostic test allergens are at risk in the EU 
 
Abstract:   
In the European Union (EU), allergens used for diagnostic tests (TAs) are defined as 
medicinal products and have to be registered by national authorities The current situation is 
not homogeneous. Existing authorizations need to be kept in the market in some EU states, 
while others need complete new authorizations requiring clinical trials, quality assurance 
methods, stability studies, and Periodic-Safety-Update-Reports. Allergen manufacturers 
argue that offering a comprehensive panel of TAs may be economically disastrous. Expenses 
for initiation and maintenance of TA-authorizations far exceed their related revenues and 
manufacturers may be forced to significantly limit their allergen portfolios. The availability 
of a wide range of high quality TAs is very important for in vivo diagnoses of IgE-mediated 
allergies. Increased regulatory demands induce costs that need to be covered by public health 
organizations or reimbursed by health insurance companies. 
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In the European Union (EU), allergens used for diagnostic tests or therapy have been defined 
as medicinal products since 1989 (1). EU-Directives 89/342/EEC and 2001/83/EC 
encompasses both diagnostic and therapeutic allergens. As a consequence, diagnostic Test 
Allergens (TAs) used in the EU have to be registered by national authorities, however, in the 
case of TAs, this process has not been completed.  
 
The assessment and approval of TAs follows the European Pharmacopoeia and the European 
Medicines Agency (EMA) Guideline on allergen products (2–5). Thus, every individual TA 
applied for each test method (e.g., for skin prick and intracutaneous tests, and conjunctival, 
nasal and bronchial provocation tests) has to be authorized in each EU Member state (4). This 
development is anticipated to have a tremendous impact on in vitro allergy diagnosis in 
Europe. 
Currently, the situation in Europe is not very homogeneous. While some EU Member states 
such as Germany, Poland and The Netherlands have authorizations for TAs in place, several 
other countries have no authorized TAs on the market. As a result, new regulatory documents 
are currently in preparation, for example in Spain (Resolución Alergenos Borrador). 
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Moreover, the authorization requirements are different in those EU member states that 
already require approval.  
Thus, we face the situation that existing authorizations need to be kept in the market in some 
EU states, while others need complete new authorizations. 
 
New authorizations 
A TA can either be registered in a single EU state, or via mutual recognition procedure with a 
state that has already approved the product referred to as reference member state or via a 
decentralized registration.  
In all procedures, clinical trials are needed to demonstrate safety, sensitivity and specificity of 
the TA (6). Such studies are of special value for allergologists and patients, however theys 
are time consuming (planning, implementation and evaluation takes up to 2 years) and costs 
of ca. 1.5million have to be calculated (for any TA, such as timothy, birch, D. 
pteronyssinus) in addition to registration costs. The registration costs for the 18 prick TA´s 
recommended as a base screening panel by GA2LEN (7) amount to estimated ca. 
12.6Million (calculated for 28 EU member states with costs of ca. 25,000 for each TA) for 
every manufacturer in the EU (4). However, fees are not harmonized between EU states. 
Costs may be even higher in Italy (where allergen manufacturers calculate registration costs 
of 55,000 per TA) and lower in Lithuania ( 712). In Germany, the fee is 11,250, but for 
parallel approval of biologically similar (homologous) groups the fee is reduced to 1125. 
TAs for intracutaneous testing and conjunctival, nasal and bronchial provocation need to be 
authorized in addition to prick TAs. 
 
In rare allergens, there may not be enough patients for a phase III trial. A solution may be the 
acceptance of data on quality and efficacy from small study populations, similar to orphan 
drugs situation. Thus, requirements should be adapted to prevalence levels across Europe. 
Additional evidence could be provided post-authorization, over the following years. 
Development of quality assurance methods and stability studies (6) induce further costs of ca. 
3500 per TA-batch/year (4), excluding personnel needed to write reports, dossiers etc. 
Stability studies according to good manufacturing practice have to include the continuous 
activity measure of at least 3 batches of a TA product over the time of use of the delivered 
TA (separately for each different skin and provocation test material).  
 
Allergen manufacturers argue that offering a comprehensive panel of TAs may be 
economically disastrous, since most of the costs are fixed and identical for “block-buster” and 
rarely used TAs (4).  
Homologous groups-formation may bring more TAs to authorization with reasonable costs 
(2). Using this method, one member of the homologous group is selected as the representative 
species. This choice should be justified considering geographical differences in sensitisation 
patterns and other relevant factors. To a limited extent, data on quality, safety and efficacy 
can be extrapolated from the representative source to other members of the homologous 
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group (2). Detailed safety studies are only requested for the representative allergen, while 
post-marketing safety reports are requested for non-representative allergens of the same 
group (2).  
 
Costs for existing TA authorizations 
Once authorization is obtained, it has to be maintained. The entire approval documentation 
must permanently be kept up to date in every member state in which the TA is authorized 
inducing costs (primarily for personnel) in the range of a six-figure euro sum (4). 
Moreover, Periodic Safety Update Reports (PSUR) have to be submitted to the national 
authorities every 6 months during the first 2 years after approval for a TA, every 12 months 
in years 3 and 4 of the approval, and every 3 years after that. PSURs report adverse events 
from routine use in the market, clinical trials and publications, allowing the authority to 
evaluate the risk–benefit potential. Depending on the complexity and amount of data, 
personnel costs of creating a PSUR can be calculated with ca. 10,000 (4). 
 
Additional processing costs of PSURs (e.g. by the Paul-Ehrlich-Institute) currently range 
from 1800–2250 for marketing authorization only in Germany, to 3600 in the case of 
mutual recognition or decentralized procedures if Germany is the reference member state, to 
2400 if it is not. The European Commission actually plans to increase the fees for 
authorities’ handling of PSURs in the second draft of the proposal (2013/0222 (COD); 
26.06.2013) to 19,500 per PSUR.  
According to Article 57 §2 of regulation 726/2004, all existing products must be entered into 
a new security database at the EMA. For every registration number, the authority estimates 
about 60 per year for the (unspecified) ‘maintenance’ of this data (6). According to 
congruent information by European manufacturers, these additional costs (including 
personnel expenses for data handling), could add up to 6000 (for registration) and 63,000 
(in associated costs) for manufacturers with a large portfolio. 
 
Consequences for patients and allergologists in routine care  
Based on these figures, it can be estimated that the expenses for initiation and maintenance of 
TA-authorizations far exceed their related revenues. Consequences for allergologists and 
patients are predictable: manufacturers may be forced to significantly limit their allergen 
portfolios for economical reasons. This has already happened in France, for example, with 
losses of about three quarters of skin prick TAs since 2004, and in Germany, where 443 
authorized TAs were lost in 2013 alone. 
For those test allergens remaining, it is unlikely that all needed in vivo test options like skin 
prick and intracutaneous tests, conjunctival, nasal and bronchial provocation tests (8) will be 
kept on the market, and significant price increases for the remaining TA´s are anticipated. 
Since most of the expenditure is fixed costs independent of the amount of TA sold, prices for 
rarely used in-vivo allergen products in particular may need to be 20 to 50 times higher than 
the price of frequently used TAs (4). In consequence, rarely used TAs may no longer be 
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commercially offered. In addition, it might be more interesting to license a broader range of 
TAs in large member states than in smaller countries., and the differences in costs for 
approval across EU member states may lead to the availability of a special TA in one country 
with its absence in another. 
 
If standardized commercial products are missing, physicians may be forced to use 
unstandardized allergens from available natural sources (native materials) not subject to 
legislative constraints. This may throw in-vivo allergy diagnoses back a century towards the 
beginnings of modern allergology and return responsibility solely to the attending physician. 
With the development of in-vitro allergy diagnoses such as IgE-measures and component 
resolved diagnosis (CRD), and with the advent of basophil activation testing, recombinant 
allergens will become increasingly more important in allergy diagnosis. However, in vitro 
assays cannot completely substitute the information given by SPT and other in vivo, allergen-
specific challenge tests that remain an essential procedure in the diagnostic work-up of the 
allergic patient.  
 
Conclusions and requests 
The availability of a wide range of high quality TAs for in vivo diagnoses of IgE-mediated 
allergies within Europe is very important for a comprehensive diagnostic procedure. 
Increased regulatory demands induce increased costs for TAs that need to be covered by 
public health organizations or reimbursed by health insurance companies in all European 
countries. 
Thus, we make the following requests for in-vivo allergy testing with TAs within Europe:  
1) Decentralized (DCP) or mutual recognition European registration processes for new 
TAs should be slimmed down and streamlined (e.g.with a quality dossier and 
reasonable clinical data).  
2) For marketed TAs, national procedures should be harmonized throughout Europe. 
3) The pharmacovigilance fees for TAs should be reduced.  
4) The homologous groups principle for TAs should achieve general acceptance.  
5) In rare TAs, data from small study populations should be accepted (i.e. quality dossier 
data plus limited clinical data). 
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